Fighting for Breath: India's Respiratory Drugs Market Driven by Severe Urban Air Pollution, High Smoking Rates
The market for Respiratory Drugs in India is significantly inflated by the severe public health crisis caused by high levels of air pollution in urban and industrial areas, which dramatically exacerbates conditions like asthma and COPD. This environmental stress drives persistent, high demand for maintenance and rescue therapies, including bronchodilators and corticosteroids.
There is a pronounced shift toward advanced delivery systems, with metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) becoming crucial for effective drug delivery and patient compliance. Pharmaceutical companies are heavily investing in developing cost-effective generic formulations to meet the large-scale need for long-term management of chronic respiratory ailments.